Engel-Nitz NM - Search Results

1

Costs and mortality of recurrent versus de novo hormone receptor-positive/HER2(-) metastatic breast cancer.

Engel-Nitz NM, Hao Y, Becker LK, Gerdes R. Engel-Nitz NM, et al. J Comp Eff Res. 2015 Aug;4(4):303-14. doi: 10.2217/cer.15.19. J Comp Eff Res. 2015. PMID: 26274792 Free article.

2

Costs and outcomes of noncardioembolic ischemic stroke in a managed care population.

Engel-Nitz NM, Sander SD, Harley C, Rey GG, Shah H. Engel-Nitz NM, et al. Vasc Health Risk Manag. 2010 Oct 5;6:905-13. doi: 10.2147/VHRM.S10851. Vasc Health Risk Manag. 2010. PMID: 20957133 Free PMC article.

3

An Evaluation of Algorithms for Identifying Metastatic Breast, Lung, or Colorectal Cancer in Administrative Claims Data.

Whyte JL, Engel-Nitz NM, Teitelbaum A, Gomez Rey G, Kallich JD. Whyte JL, et al. Med Care. 2015 Jul;53(7):e49-57. doi: 10.1097/MLR.0b013e318289c3fb. Med Care. 2015. PMID: 23524464

4

Service setting impact on costs for bevacizumab-treated oncology patients.

Engel-Nitz NM, Yu EB, Becker LK, Small A. Engel-Nitz NM, et al. Am J Manag Care. 2014 Nov 1;20(11):e515-22. Am J Manag Care. 2014. PMID: 25730350 Free article.

5

Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer.

Reyes C, Engel-Nitz NM, DaCosta Byfield S, Ravelo A, Ogale S, Bancroft T, Anderson A, Chen M, Matasar M. Reyes C, et al. Oncologist. 2019 Sep;24(9):1209-1218. doi: 10.1634/theoncologist.2018-0018. Epub 2019 Feb 22. Oncologist. 2019. PMID: 30796156 Free PMC article.

6

Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.

Engel-Nitz NM, Johnson MP, Bunner SH, Ryan KJ. Engel-Nitz NM, et al. J Manag Care Spec Pharm. 2020 Jun;26(6):729-740. doi: 10.18553/jmcp.2020.26.6.729. J Manag Care Spec Pharm. 2020. PMID: 32463768 Free PMC article.

7

Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer.

Engel-Nitz NM, Johnson MG, Johnson MP, Cha-Silva AS, Kurosky SK, Liu X. Engel-Nitz NM, et al. Patient Prefer Adherence. 2023 Apr 18;17:1049-1062. doi: 10.2147/PPA.S401480. eCollection 2023. Patient Prefer Adherence. 2023. PMID: 37096162 Free PMC article.

8

Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population.

Engel-Nitz NM, Alemayehu B, Parry D, Nathan F. Engel-Nitz NM, et al. Cancer Manag Res. 2011;3:233-45. doi: 10.2147/CMR.S21033. Epub 2011 Jul 4. Cancer Manag Res. 2011. PMID: 21792332 Free PMC article.

9

Diagnostic testing managed by hematopathology specialty and other laboratories: costs and patient diagnostic outcomes.

Engel-Nitz NM, Eckert B, Song R, Koka P, Hulbert EM, McPheeters J, Teitelbaum A. Engel-Nitz NM, et al. BMC Clin Pathol. 2014 Apr 27;14:17. doi: 10.1186/1472-6890-14-17. eCollection 2014. BMC Clin Pathol. 2014. PMID: 24817828 Free PMC article.

10

Cost of Disease Progression in Patients with Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non-Hodgkin's Lymphoma.

Reyes C, Engel-Nitz NM, DaCosta Byfield S, Ravelo A, Ogale S, Bancroft T, Anderson A, Chen M, Matasar M. Reyes C, et al. Oncologist. 2019 Sep;24(9):1219-1228. doi: 10.1634/theoncologist.2018-0019. Epub 2019 Feb 26. Oncologist. 2019. PMID: 30808814 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

32 results

Search Page

Filters